CME Lesson

Safety of Baricitinib 4 mg for the Treatment of Rheumatoid Arthritis

Click the Play button above to access the podcast.

Subscribe: AppleGoogleSpotifyYouTubeiHeartRadioStitcher Radio

References & Resources

  1. Dabal TD, Halton MB, Patel PP, et al. Safety of baricitinib for 4 mg for the treatment of moderate to severe rheumatoid arthritis. South Med J 2021;114:288-292.
  2. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
  3. Keystone EC, Genovese MC, Schlichting DE, et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. J Rheumatol 2018;45:14–21.
  4. Eli Lilly and Company. FDA Briefing Document. Arthritis Advisory Committee Meeting, April 23, 2018. NDA 207924, Baricitinib Janus Kinase (JAK) inhibitor for RA. https://www.fda.gov/media/112372/download. Published 2018. Accessed February 28, 2021.Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755–1766.

After reviewing the content and resources, click below to take the course quizzes.